Copy number variations and expression of MPDZ are prognostic biomarkers for clear cell renal cell carcinoma

• Published in: Oncotarget 2017-10, Vol.8 (45), p.78713-78725
• Main Authors: Huang, Yong-Sheng, Liu, Wen-Bin, Han, Fei, Yang, Jun-Tang, Hao, Xiang-Lin, Chen, Hong-Qiang, Jiang, Xiao, Yin, Li, Ao, Lin, Cui, Zhi-Hong, Cao, Jia, Liu, Jin-Yi
• Format: Article
• Language: English
• Subjects: Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.20220

The vital copy number variation (CNV) plays a crucial role in clear cell renal cell carcinoma (ccRCC). MPDZ inhibit cell polarity associate with osmotic pressure response and cancer-related biological processes. In order to clarify the role of the CNV of in the progression of ccRCC, we analyzed the CNV and expression of and prognosis in ccRCC patients from The Cancer Genome Atlas data portal. Notably, we found that the deletion of was the common CNV, which was present in 28.65% of ccRCC patients. With the development of tumors, the percentage of deletion increased significantly (19.38% in stage I; 20.00% in stage II; 40.94% in stage III; and 45.00% in stage IV). The deletion of significantly increased ccRCC risk (P=0.0025). Low expression associated with its deletion was significantly associated with adverse outcomes in ccRCC patients (P=0.0342). Furthermore, immunohistochemical analysis by tissue microarray showed that MPDZ was expressed at lower levels in tumor tissues compared with adjacent tissues (P